Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
GLOBETECH PUBLISHING LLC
Ampronix

PET-CT Identifies Ruptured and High-Risk Coronary Plaque

By Medimaging International staff writers
Posted on 09 Jan 2014
Image: The Biograph mCT PET-CT system by Siemens Healthcare (Photo courtesy of Siemens Healthcare).
Image: The Biograph mCT PET-CT system by Siemens Healthcare (Photo courtesy of Siemens Healthcare).
Scientists have discovered that the tracer 18F-sodium fluoride (18F-NaF) used with positron emission tomography-computed tomography (PET-CT) imaging technology is the first noninvasive imaging modality to identify and localize ruptured and high-risk coronary plaque.

The University of Edinburgh (Scotland, UK) is leading the heart disease study with the help of a Biograph mCT PET-CT system developed by Siemens Healthcare (Erlangen, Germany). The new study’s findings were published October 2013 in the Lancet. Currently there is no noninvasive way of finding high-risk plaques at risk of rupturing and causing a heart attack. The imaging technology is providing new clues into clinical research into early diagnosis of the disorder.

In the prospective clinical trial, patients with myocardial infarction and stable angina underwent 18F-NaF and 18F-fluorodeoxyglucose (18F-FDG) PET-CT and invasive coronary angiography. 18F-NaF uptake was compared with histology in carotid endarterectomy specimens from patients with symptomatic carotid disease, and with intravascular ultrasound in patients with stable angina. The primary endpoint was the comparison of 18F-fluoride tissue-to-background ratios of culprit and non-culprit coronary plaques of patients with acute myocardial infarction.

In 93% (37) of patients with myocardial infarction, the highest coronary 18F-NaF uptake was seen in the culprit plaque. By contrast, coronary 18F-fluorodeoxyglucose (FDG) uptake was typically concealed by myocardial uptake and where discernible, there were no differences between culprit and non-culprit plaques. Marked 18F-NaF uptake occurred at the site of all carotid plaque ruptures and was linked with histologic evidence of active calcification, macrophage infiltration, apoptosis, and necrosis. Forty-five percent (18) of patients with stable angina had plaques with focal 18F-NaF uptake that were associated with more high-risk features on intravascular ultrasound than those without uptake.

The plaque areas in the blood vessels were easily identifiable by using the Biograph mCT scanner. In the patients with angina, advanced notice that they had high-risk plaques and a heart attack may be impending. These patients could then be targeted with aggressive therapy to avoid future events.

“Being able to identify dangerous fatty plaques likely to cause a heart attack is something that conventional heart tests can’t do. This research suggests that PET-CT scanning may provide an answer, identifying ‘ticking time bomb’ patients at risk of a heart attack,” said Prof. Peter Weissberg, medical director at the British Heart Foundation (BHF; London, UK). “Nearly 20 years of BHF-funded research has led us to this point. We now need to confirm these findings, and then understand how best to use new tests like this in the clinic to benefit heart patients.”

BHF clinical lecturer and cardiologist Dr. Marc Dweck, who led the research at the University of Edinburgh, stated: “We have developed what we hope is a way to ‘light up’ plaques on the brink of rupturing and causing a heart attack. If we could know how close a person is to having a heart attack, we could step in with medication or surgery before the damage is done. This is a first step towards that goal. The next stage is to confirm these findings in larger studies to establish first that this technique can truly predict heart attacks and secondly that treatment can help patients avoid these events.”

“Siemens Healthcare is delighted that the Biograph mCT is aiding ground-breaking research into the UK’s biggest killer—heart disease,” remarked Lawrence Foulsham, business manager, molecular imaging at Siemens Healthcare. “The condition is a clinical priority for the UK; therefore advancements in this field are incredibly important. We have a long-standing partnership with the Clinical Research Imaging Center at the University of Edinburgh and look forward to assisting them with further clinical research insights into the future.”

The Clinical Research Imaging Center at the University of Edinburgh installed the Biograph mCT in 2010.

Related Links:

Siemens Healthcare
University of Edinburgh



Channels

MRI

view channel
Image: MR Solutions Conversion Kit for MRI Scanner (Photo courtesy of MR Solutions).

Conversion Kit Transforms Clinical MRI System into a Preclinical Scanner

A clinical Magnetic Resonance Imaging (MRI) scanner can now be transformed into an effective preclinical system using a simple conversion kit. The transformation can be carried out in approximately... Read more

Ultrasound

view channel
Image: World’s first 29 MHz micro-ultrasound system (Photo courtesy of Exact Imaging).

Breakthrough High-Resolution Micro-Ultrasound Platform for the Prostate Revealed at AUA 2015

A novel micro-ultrasound imaging platform has been introduced at the annual meeting of the American Urological Association (AUA) 2015 (New Orleans, LA, USA). The probe operates at 29 MHz, and enables... Read more

Nuclear medicine

view channel

Human Prostate Cancer Study Evaluates New Imaging Biomarker

The results of the first human prostate cancer study intended to evaluate a 2nd generation fluorine-18 labeled small-molecule PSMA inhibitor, have been published in the April 28, 2015, issue of the Journal of Molecular Imaging and Biology. The results of the evaluation demonstrated the initial safety, bio-distribution,... Read more

General/Advanced Imaging

view channel

Global Healthcare Study of Coronary Artery Disease Reaches Significant Milestone

A major milestone has been reached in the Lipid-Rich Plaque (LRP) study, a prospective, multicenter clinical trial with the potential to reveal breakthrough correlations between Lipid-Rich Plaques and occurrence of heart attacks. The LPR study has now enrolled 1,000 patients, and aims to identify a correlation between... Read more

Imaging IT

view channel
Image: Carestream Vue Motion Viewer (Photo courtesy of Carestream Healthcare).

New Software Solution Facilitates Secure Data Aggregation from Existing Hospital IT Systems

A medical imaging systems and Information Technology (IT) solutions provider has demonstrated how its advanced healthcare IT software solutions can facilitate high-quality imaging access, and improved... Read more

Industry News

view channel

Advanced Medical Imaging Startup Company Receives Venture Funding

Zebra Medical Vision (Kibbutz Shfayim, Israel) has received an USD 8 million investment from Khosla Ventures (Menlo Park, CA, USA) to double its team, set up headquarters in the US and increase its scope of work to integrate data from additional Health Maintenance Organizations (HMO). Zebra Medical has already partnered... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.